MitoRx Therapeutics secures investment from Science Angel Syndicate to develop its first-in-class therapeutics that target dysfunctional sulfide-signalling in mitochondria to halt the progress of degenerative diseases.

Science Angel Syndicate (SAS) was launched in September 2021 to supportinvestments into frontier scientific discoveries that impact society on a global scale. Leveraging their unique due diligence capabilities they have supported SAS investors to make an investment into MitoRx Therapeutics. 

52 North Health, a UK and US-based med-tech start-up, has raised £1 million in its first round of funding from leading UK and European specialist investors. The round was led by Cambridge Enterprise, the commercialisation arm of the University of Cambridge, with participation from Crista Galli Ventures, King’s Health Partners MedTech Innovations, Meltwind, Milltrust Ventures and a number of angels.

SETsquared Bristol member LatchAid, an award winning breastfeeding and early parenthood support innovator, has closed its seed funding round with an ultra-competitive £510k Innovate UK Innovation Loan, bringing total investments to £1m, as testament to its ground-breaking technology and user traction.

Biomedical startup Adapttech has raised £2.25 million from investors including Mercia Asset Management, ACF Investors, Wren Capital and Wealth Club. The company also announced the launch of the new INSIGHT Range, a family of products that make it faster and easier to fit lower-limb prostheses and improve patient outcomes.

Sano Genetics, co-founded by three University of Cambridge genomics postgraduates, has raised $11M in a Series A funding round led by MMC Ventures, with further funding from Episode 1, Seedcamp and several angel investors, including Paul Forster, a co-founder and former CEO of Indeed, Paul Wicks, former VP of innovation at PatientsLikeMe, and Margo Georgiadis, the former CEO of Ancestry.com.

Award-winning hybrid studio and digital fitness platform BLOK has  secured £3.75m in a funding round led by ACF Investors, with additional investment from Elcot  Capital and The Santon Group. The funding round also included investment from the UK  government’s Future Fund, Crowdcube and angel investor Rob Wirszycz, who will be joining the  business as Chairman.  

Tonic Health, a natural healthcare company that combines all-in-one vitamins, minerals and plants into a drink that fuels the immune system to help end unnecessary illness, has received investment from Henley Business Angels as part of a £463,000.funding round.

Our member and University of Bristol spin-out, FluoretiQ, has today announced the completion of a £1.1 million, pre-series A investment. Their pioneering NANOPLEX technology is a 15-minute proprietary diagnostic platform for bacterial infections.  

Semarion Ltd, a University of Cambridge spin-out company from the Cavendish Laboratory combining materials engineering and cell biology to tackle unmet drug screening needs, has closed a £2.14 million GBP seed funding round. The investment round was led by Parkwalk Advisors, with the University of Cambridge Seed Funds, Martlet Capital, and angel investors also contributing to the fundraise.

A young British business owner who was declared “Britain’s best boss” after he let his staff have the day off on full pay when lockdown restrictions lifted last year has raised £2.5M in seed funding for new elderly care search platform, Lottie, just six months after winning initial backing off Monzo’s founder to launch it.  Exasperated by their own experience of searching for a care home for their Grandma, entrepreneur Chris Donnelly and healthcare expert brother Will Donnelly, launched Lottie in July 2021 - a free digital healthcare marketplace, helping families minimize the time, stress and cost of finding quality compassionate care homes.

Atelerix, a business at the forefront of cell preservation with aims to revolutionise the way we store, and transport cells and tissues, has raised £425,574 investment to help fully commercialise their product and bring it to market.

Deepbridge Capital portfolio company AlgaeCytes has secured €16m of funding to develop a commercial plant in Germany.  AlgaeCytes is a portfolio company within the Deepbridge Technology Growth EIS.